{"id":"placebo-for-aspirin-300","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is a non-therapeutic substance used in randomized controlled trials to provide a blinded control arm. Any observed effects in the placebo group represent natural disease progression, regression to the mean, or the placebo effect itself. This allows researchers to isolate the true pharmacological effects of Aspirin 300 by comparison.","oneSentence":"Placebo has no active pharmacological mechanism; it serves as an inert control in clinical trials to establish baseline efficacy and safety of the active comparator (Aspirin 300).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:04.353Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 trial comparing Aspirin 300 efficacy and safety"}]},"trialDetails":[{"nctId":"NCT05310968","phase":"PHASE4","title":"Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-11-12","conditions":"Branch Atheromatous Disease","enrollment":970},{"nctId":"NCT07275749","phase":"PHASE3","title":"Acetyl-leucine in Post-stroke Ataxia","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2025-12-01","conditions":"Ischemic Stroke","enrollment":200},{"nctId":"NCT06414499","phase":"PHASE3","title":"Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-07-09","conditions":"Minor Ischemic Stroke","enrollment":1386},{"nctId":"NCT02813824","phase":"PHASE3","title":"Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-11-14","conditions":"Lynch Syndrome","enrollment":852},{"nctId":"NCT04575519","phase":"PHASE2","title":"Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis","status":"RECRUITING","sponsor":"Fundació Institut Germans Trias i Pujol","startDate":"2021-03-04","conditions":"Tuberculosis, Pulmonary, Tuberculosis, MDR, Tuberculosis Infection","enrollment":354},{"nctId":"NCT05797597","phase":"PHASE3","title":"Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease","status":"UNKNOWN","sponsor":"Lucyna Mastalerz","startDate":"2022-12-07","conditions":"AERD - Aspirin Exacerbated Respiratory Disease","enrollment":76},{"nctId":"NCT02906761","phase":"PHASE3","title":"Aspirin for Uncontrolled Asthma","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-01-15","conditions":"Uncontrolled Asthma","enrollment":24},{"nctId":"NCT03698513","phase":"PHASE1","title":"A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-04","conditions":"Healthy Volunteers","enrollment":113},{"nctId":"NCT05045274","phase":"NA","title":"The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-12","conditions":"STEMI - ST Elevation Myocardial Infarction, Left Ventricular Systolic Dysfunction","enrollment":300},{"nctId":"NCT04808895","phase":"PHASE3","title":"Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients With COVID-19","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2021-04-01","conditions":"COVID-19, Thrombosis Pulmonary","enrollment":204},{"nctId":"NCT03595488","phase":"PHASE2","title":"Dupilumab for Aspirin-exacerbated Respiratory Disease","status":"COMPLETED","sponsor":"Rochester General Hospital","startDate":"2018-09-05","conditions":"Aspirin-exacerbated Respiratory Disease","enrollment":11},{"nctId":"NCT00979589","phase":"PHASE3","title":"Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2009-12","conditions":"Stroke, Transient Ischemic Attack","enrollment":5100},{"nctId":"NCT04407312","phase":"PHASE4","title":"Cilostazol and Endothelial Progenitor Cell","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","startDate":"2016-01-01","conditions":"Myocardial Infarction, Acute","enrollment":60},{"nctId":"NCT02776540","phase":"PHASE4","title":"Clopidogrel for Acute Ischaemia of Recent Onset","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2016-06-01","conditions":"Ischemic Cerebrovascular Accident","enrollment":188},{"nctId":"NCT03341117","phase":"PHASE3","title":"Acetylsalicylic Acid and Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2014-12-02","conditions":"Diabetes Mellitus, Type 2, Antioxidant Enzyme System","enrollment":21},{"nctId":"NCT02155985","phase":"PHASE2","title":"Modulation of Immune Activation by Aspirin","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-08","conditions":"HIV-1 Infection","enrollment":121},{"nctId":"NCT03078257","phase":"PHASE1","title":"Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-01-01","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT00249795","phase":"PHASE3","title":"Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Atrial Fibrillation, Cardiovascular Disease","enrollment":9016},{"nctId":"NCT00938522","phase":"PHASE4","title":"Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2009-07","conditions":"Angioplasty, Transluminal, Percutaneous Coronary","enrollment":400},{"nctId":"NCT00898950","phase":"NA","title":"Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Portsmouth","startDate":"2004-08","conditions":"Diabetes Type 2","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":66,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo300"],"phase":"phase_3","status":"active","brandName":"Placebo (for Aspirin 300)","genericName":"Placebo (for Aspirin 300)","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo has no active pharmacological mechanism; it serves as an inert control in clinical trials to establish baseline efficacy and safety of the active comparator (Aspirin 300). Used for Control arm in Phase 3 trial comparing Aspirin 300 efficacy and safety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}